Ambagon Therapeutics
Ambagon is discovering and developing small molecule cancer drugs that stabilize the direct interaction of oncogenic proteins with the 14-3-3 class of adaptor proteins. Ambagon’s platform approach will open opportunities to address major unmet clinical needs beyond oncology.
7-day free trial · no credit card
Verified contacts
17
available on Kipplo
LinkedIn employees
17
11 to 50 range
Open roles
—
no listings
Distinct roles
14
indexed titles
Tech stack
1
tools in use
Monthly traffic
76
organic / mo
Sign up free to see all 17 verified contacts at Ambagon Therapeutics
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
17 contacts with verified email or phone · masked until revealed.
- YZ
Ying Zhang
Executive Director · General Business & Management
EmailPhone - LD
Laura Demmers
Senior Scientist · Science
EmailPhone - MA
Maarten Altelaar
() · Other
EmailPhone - TM
Tanja Meyer
VP & Head, Corporate Strategy & Business Development · Other
EmailPhone - LS
Loes Stevers
Principal Scientist Biochemistry · Other
EmailPhone - RD
Rens de Vries
Senior Scientist · Science
EmailPhone - CO
Christian Ottmann
Founder, CTO · Other
EmailPhone - DL
David Len Elion
Novasenta · Other
EmailPhone - DO
Donna Olivia Debets
Senior Scientist Proteomics · Other
EmailPhone
Showing 9 of 17 verified contacts
Top roles at Ambagon Therapeutics
14 distinct titles indexed · top 10 shown.
- 4senior scientist
- 1()
- 1chief technology officer
- 1executive director
- 1founder, cto
- 1novasenta
- 1principal scientist biochemistry
- 1research intern
- 1scientist
- 1scientist biochemistry
- +4more titles
Sign up to unlock all 17 contacts at Ambagon Therapeutics
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 17 verified contacts at Ambagon Therapeutics
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.